Evidence map›Paper›PMID 36676422›Full record

ArticleMaterials (Basel, Switzerland)2023

A Novel Chitosan Composite Biomaterial with Drug Eluting Capacity for Maxillary Bone Regeneration.

Barbara Giordano-Kelhoffer, Raquel Rodríguez-Gonzalez, Marina Perpiñan-Blasco, Jenifer O Buitrago, Begoña M Bosch, Roman A Perez

Open access · goldAbstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Barbara Giordano-KelhofferBioengineering Institute of Technology, Universitat Internacional de Catalunya (UIC), 08017 Barcelona, Spain.
Raquel Rodríguez-GonzalezBioengineering Institute of Technology, Universitat Internacional de Catalunya (UIC), 08017 Barcelona, Spain.
Marina Perpiñan-BlascoBioengineering Institute of Technology, Universitat Internacional de Catalunya (UIC), 08017 Barcelona, Spain.
Jenifer O BuitragoBioengineering Institute of Technology, Universitat Internacional de Catalunya (UIC), 08017 Barcelona, Spain.ORCID 0000-0002-7273-1086
Begoña M BoschBioengineering Institute of Technology, Universitat Internacional de Catalunya (UIC), 08017 Barcelona, Spain.ORCID 0000-0002-6965-0234
Roman A PerezBioengineering Institute of Technology, Universitat Internacional de Catalunya (UIC), 08017 Barcelona, Spain.ORCID 0000-0002-0823-2303
Universitat Internacional de Catalunya · ES

Funding

Ministerio de ciencia e innovación RYC2018-025977-IMinisterio de Ciencia e innovación RTI2018-096088-J-100
6 · The paper itself

Abstract

Bone grafting is one of the most commonly performed treatments for bone healing or repair. Autografts, grafts from the same patient, are the most frequently used bone grafts because they can provide osteogenic cells and growth factors at the site of the implant with reduced risk of rejection or transfer of diseases. Nevertheless, this type of graft presents some drawbacks, such as pain, risk of infection, and limited availability. For this reason, synthetic bone grafts are among the main proposals in regenerative medicine. This branch of medicine is based on the development of new biomaterials with the goal of increasing bone healing capacity and, more specifically in dentistry, they aim at simultaneously preventing or eliminating bacterial infections. The use of fibers made of chitosan (CS) and hydroxyapatite (HA) loaded with an antibiotic (doxycycline, DX) and fabricated with the help of an injection pump is presented as a new strategy for improving maxillary bone regeneration. In vitro characterization of the DX controlled released from the fibers was quantified after mixing different amounts of HA (10-75%). The 1% CS concentration was stable, easy to manipulate and exhibited adequate cuttability and pH parameters. The hydroxyapatite concentration dictated the combined fast and controlled release profile of CSHA50DX. Our findings demonstrate that the CS-HA-DX complex may be a promising candidate graft material for enhancing bone tissue regeneration in dental clinical practice.

Indexed as

bone graftchitosandoxycyclinehydroxyapatite

Identifiers

PMID36676422
PMCPMC9866710
OpenAlexW4315647923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.